Compare EGY & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EGY | CRMD |
|---|---|---|
| Founded | 1985 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.3M | 626.0M |
| IPO Year | 1996 | 2009 |
| Metric | EGY | CRMD |
|---|---|---|
| Price | $5.54 | $8.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.30 | ★ $14.83 |
| AVG Volume (30 Days) | 1.1M | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.75% | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 0.43 |
| Revenue | ★ $359,272,000.00 | $311,709,000.00 |
| Revenue This Year | $8.78 | $0.30 |
| Revenue Next Year | $29.81 | N/A |
| P/E Ratio | ★ N/A | $20.38 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $3.36 | $6.13 |
| 52 Week High | $6.72 | $17.43 |
| Indicator | EGY | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 49.21 | 59.32 |
| Support Level | $5.53 | $8.09 |
| Resistance Level | $5.65 | $9.01 |
| Average True Range (ATR) | 0.21 | 0.30 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 81.82 | 60.30 |
VAALCO Energy Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids (NGLs). It has a diversified, African-focused portfolio of production, development, and exploration assets located in Gabon, Egypt, Cote d'Ivoire, Equatorial Guinea, and Nigeria, which are also considered its reportable operating segments. Maximum revenue is generated from the Gabon segment, which holds working interest in and operates the Etame Marin block, located offshore Gabon. The company derives all of its revenue from crude oil, natural gas, and natural gas liquids sales.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.